Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

107.78
Delayed Data
As of Aug 28
 -0.21 / -0.19%
Today’s Change
85.95
Today|||52-Week Range
123.37
+14.34%
Year-to-Date
4 Not-Too-Scary Ways to Make Money on Biotech Stocks
7:01am / MotleyFool.com
3 Drugs Stocks Nudging The Industry Higher
Aug 24 / TheStreet.com
Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
Aug 28 / Zacks.com
Biotech Stocks Recover From Early-Morning Flash Crash
Aug 24 / TheStreet.com
Exelixis Up on Swiss Approval of Advanced Melanoma Drug
Aug 28 / Zacks.com
US 'big four' biotechs lead sector tumble into bear market
Aug 24 / FT.com
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval
Aug 28 / Zacks.com
Stock Futures Plunge: 4 Value Stocks Brokers Love Right Now
Aug 24 / Zacks.com
Stock Market News for August 27, 2015
Aug 27 / Zacks.com
Raptor Pharmaceuticals (RPTP) in Focus: Stock Adds 5.8%
Aug 24 / Zacks.com
J&J to Sell Sugar Substitute Splenda to Heartland Food
Aug 26 / Zacks.com
Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session
Aug 24 / Zacks.com
Eli Lilly's Alimta Patent Upheld by U.S. District Court
Aug 26 / Zacks.com
Keep Calm and Shop for Bargains
Aug 24 / TheStreet.com
Novartis' (NVS) Promacta Label Further Expanded in U.S.
Aug 26 / Zacks.com
6 Things You Should Know About a Stock Market Correction
Aug 24 / MotleyFool.com
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Aug 26 / Zacks.com
Gilead (GILD) Is Today's Pre-Market Laggard Stock
Aug 24 / TheStreet.com
You Can't Keep Volatility Down Forever
Aug 26 / TheStreet.com
Bad News for Hepatitis C Patients: Your Treatment Costs May Be Higher Than Expected
Aug 22 / MotleyFool.com
Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher
Aug 26 / Zacks.com
Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio
Aug 21 / Zacks.com
Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session
Aug 26 / Zacks.com
Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study
Aug 21 / Zacks.com
What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?
Aug 26 / Zacks.com
Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move?
Aug 21 / Zacks.com
4 Notable Stocks Still Green After Late Tuesday Sell-Off
Aug 25 / Zacks.com
Gilead's EU Regulatory Application for HIV Drug Validated
Aug 21 / Zacks.com
Nasdaq Slips into Correction: 4 Stocks Stand Tall
Aug 25 / Zacks.com
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Aug 21 / Zacks.com
Medivation to Gain Global Rights to BioMarin's Talazoparib
Aug 25 / Zacks.com
America's favorite stocks in bear market territory
Aug 21 / CNNMoney.com
AstraZeneca, Peregrine Team Up for Immuno-Oncology Study
Aug 25 / Zacks.com
Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)
Aug 21 / Zacks.com
Bouncing Biotech? 3 Stocks To Buy
Aug 25 / MotleyFool.com
Argos Therapeutics (ARGS) Jumps: Stock Moves Up 12%
Aug 21 / Zacks.com
Gilead (GILD) Stock Storming The Castle Today
Aug 25 / TheStreet.com
Did AbbVie Just Make an Incredibly Brilliant Decision?
Aug 21 / MotleyFool.com
The Zacks Analyst Blog Highlights: Gilead Sciences, DSW, Cardtronics and CECO Environ...
Aug 25 / Zacks.com
United Therapeutics to Sell Priority Review Voucher to AbbVie
Aug 20 / Zacks.com
Epizyme (EPZM) Shows Strength: Stock Adds 9.6% in Session
Aug 25 / Zacks.com
Vical's Antifungal Candidate VL-2397 Receives QIDP Status
Aug 20 / Zacks.com
An Inside Look at Biotech Investor Pros Dealing With Market Meltdown
Aug 25 / TheStreet.com
BioMarin's Drisapersen Gets Rare Pediatric Disease Status
Aug 20 / Zacks.com
Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Aug 24 / Zacks.com
Illumina (ILMN) Creates Helix to Encourage Genomics Startups
Aug 20 / Zacks.com
Alkermes' (ALKS) Aristada Review Date Postponed by FDA
Aug 24 / Zacks.com
Weakness Seen in TrovaGene (TROV) Estimates: Should You Stay Away?
Aug 20 / Zacks.com
Flash Crash-Like Selloff Met by Buyers; Cookbs Letter to Cramer Was bSignificantb
Aug 24 / TheStreet.com
Bellerophon Therapeutics (BLPH) Jumps: Stock Rises 15.8%
Aug 20 / Zacks.com